Targeting calcium signaling in cancer therapy

Acta Pharmaceutica Sinica B

Volumn 7, Issue 1, 2017, Pages 3-17

  Cui, Chaochu ^a,b   Merritt, Robert ^b,c   Fu, Liwu ^a   Pan, Zui ^b,c,d  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

Author keywords

Apoptosis; Ca2+ channels; Cancer therapy; Cell proliferation; Channel blockers; ; Migration; Store operated Ca2+ entry

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE INHIBITOR; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL; CAPSAICIN; GSK 1016790A; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; MIBEFRADIL; PURINERGIC RECEPTOR; PYRAZOLE DERIVATIVE; STROMAL INTERACTION MOLECULE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR AGONIST; VOLTAGE GATED CALCIUM CHANNEL;

APOPTOSIS; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CANCER CELL; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CELL MEMBRANE; CHEMOSENSITIVITY; DRUG EFFICACY; DRUG TARGETING; ENDOPLASMIC RETICULUM; GLIOMA; HUMAN; MITOCHONDRION; MOUTH SQUAMOUS CELL CARCINOMA; NEUROLOGIC DISEASE; NONHUMAN; PANCREAS CANCER; REVIEW; STIMULATION;

EID: 85008234696     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2016.11.001     Document Type: Review

References (211)

1. 1 Berridge, M.J., Lipp, P., Bootman, M.D., The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 1 (2000), 11–21.
2. 2 Csordas, G., Varnai, P., Golenar, T., Roy, S., Purkins, G., Schneider, T.G., et al. Imaging interorganelle contacts and local calcium dynamics at the ER-mitochondrial interface. Mol Cell 39 (2010), 121–132.
3. 3 Parkash, J., Asotra, K., Calcium wave signaling in cancer cells. Life Sci 87 (2010), 587–595.
4. 4 McConkey, D.J., Orrenius, S., The role of calcium in the regulation of apoptosis. Biochem Biophys Res Commun 239 (1997), 357–366.
5. 5 Baudouin-Legros, M., Brouillard, F., Tondelier, D., Hinzpeter, A., Edelman, A., Effect of ouabain on CFTR gene expression in human Calu-3 cells. Am J Physiol Cell Physiol 284 (2003), C620–C626.
6. 2+ oscillations in human esophageal squamous cell carcinoma. Oncotarget 5 (2014), 3455–3471.
7. 2+ oscillations. Trends Biochem Sci 36 (2011), 78–87.
8. 8 Berridge, M.J., The AM and FM of calcium signalling. Nature 386 (1997), 759–760.
9. 9 Smedler, E., Uhlen, P., Frequency decoding of calcium oscillations. Biochim Biophys Acta, 2013.
10. 10 Cullen, P.J., Calcium signalling: the ups and downs of protein kinase C. Curr Biol 13 (2003), R699–R701.
11. 2+]i Oscillation frequency regulates agonist-stimulated NF-κB transcriptional activity. J Biol Chem 274 (1999), 33995–33998.
12. 12 Dolmetsch, R.E., Xu, K., Lewis, R.S., Calcium oscillations increase the efficiency and specificity of gene expression. Nature 392 (1998), 933–936.
13. 13 Kondratskyi, A., Yassine, M., Kondratska, K., Skryma, R., Slomianny, C., Prevarskaya, N., Calcium-permeable ion channels in control of autophagy and cancer. Front Physiol, 4, 2013, 272.
14. 14 Gu, J., Liu, H., Fu, T., Xu, Y., Thapsigargin increases apoptotic cell death in human hepatoma BEL-7404 cells. Cell Res 5 (1995), 59–65.
15. 15 Vandewalle, B., Hornez, L., Wattez, N., Revillion, F., Lefebvre, J., Vitamin-D3 derivatives and breast-tumor cell growth: effect on intracellular calcium and apoptosis. Int J Cancer 61 (1995), 806–811.
16. 2+ pump. J Biol Chem 276 (2001), 26737–26740.
17. 2+ for cancer cell proliferation and survival. Nat Rev Cancer 8 (2008), 361–375.
18. 18 Gkika, D., Prevarskaya, N., TRP channels in prostate cancer: the good, the bad and the ugly?. Asian J Androl 13 (2011), 673–676.
19. 2+/calmodulin—dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression. J Biol Chem 287 (2012), 24832–24843.
20. 20 Monteith, G.R., Davis, F.M., Roberts-Thomson, S.J., Calcium channels and pumps in cancer: changes and consequences. J Biol Chem 287 (2012), 31666–31673.
21. 3 receptors and their role in cell function. Joachim, K., Marek, M., (eds.) New Comprehensive Biochemistry, 2007, Amsterdam: Elsevier, 267–285.
22. 2+-release channel. Biochim Biophys Acta 1853 (2015), 1992–2005.
23. 2+ transfer from the ER to mitochondria: when, how and why. Biochim Biophys Acta 1787 (2009), 1342–1351.
24. 24 Kang, S.S., Han, K.S., Ku, B.M., Lee, Y.K., Hong, J., Shin, H.Y., et al. Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. Cancer Res 70 (2010), 1173–1183.
25. 3R3) in the peritoneal dissemination of gastric cancers. Anticancer Res 23 (2003), 3691–3697.
26. 26 Shibao, K., Fiedler, M.J., Nagata, J., Minagawa, N., Hirata, K., Nakayama, Y., et al. The type III inositol 1,4,5-trisphosphate receptor is associated with aggressiveness of colorectal carcinoma. Cell calcium 48 (2010), 315–323.
27. 27 Hedberg, M.L., Goh, G., Chiosea, S.I., Bauman, J.E., Freilino, M.L., Zeng, Y., et al. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest 126 (2016), 169–180.
28. 3R-derived peptide targeting the BH4 domain of Bcl-2. Cell Death Dis, 4, 2013, e632.
29. 2+ signalling in thymocytes leads to aberrant development and acute lymphoblastic leukemia. Nat Commun, 5, 2014, 4814.
30. 30 Krebs, J., The plethora of PMCA isoforms: alternative splicing and differential expression. Biochim Biophys Acta 1853 (2015), 2018–2024.
31. 31 Dang, D., Rao, R., Calcium-ATPases: gene disorders and dysregulation in cancer. Biochim Biophys Acta, 2015.
32. 32 Fan, L., Li, A., Li, W., Cai, P., Yang, B., Zhang, M., et al. Novel role of Sarco/endoplasmic reticulum calcium ATPase 2 in development of colorectal cancer and its regulation by F36, a curcumin analog. Biomed Pharmacother 68 (2014), 1141–1148.
33. 33 Brouland, J.P., Gelebart, P., Kovacs, T., Enouf, J., Grossmann, J., Papp, B., The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis. Am J Pathol 167 (2005), 233–242.
34. 34 Dellis, O., Arbabian, A., Brouland, J.P., Kovacs, T., Rowe, M., Chomienne, C., et al. Modulation of B-cell endoplasmic reticulum calcium homeostasis by Epstein–Barr virus latent membrane protein-1. Mol Cancer, 8, 2009, 59.
35. 35 Grice, D.M., Vetter, I., Faddy, H.M., Kenny, P.A., Roberts-Thomson, S.J., Monteith, G.R., Golgi calcium pump secretory pathway calcium ATPase 1 (SPCA1) is a key regulator of insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA-MB-231. J Biol Chem 285 (2010), 37458–37466.
36. 36 Feng, M., Grice, D.M., Faddy, H.M., Nguyen, N., Leitch, S., Wang, Y., et al. Store-independent activation of Orai1 by SPCA2 in mammary tumors. Cell 143 (2010), 84–98.
37. 37 Lee, W.J., Roberts-Thomson, S.J., Monteith, G.R., Plasma membrane calcium-ATPase 2 and 4 in human breast cancer cell lines. Biochem Biophys Res Commun 337 (2005), 779–783.
38. 2+-ATPase expression during colon cancer cell line differentiation. Biochem Biophys Res Commun 355 (2007), 932–936.
39. 2+ ATPase isoform 1 down-regulated in human oral cancer. Oncol Rep 15 (2006), 49–55.
40. 2+ channels. Annu Rev Cell Dev Biol 16 (2000), 521–555.
41. 41 Wang, C.Y., Lai, M.D., Phan, N.N., Sun, Z., Lin, Y.C., Meta-analysis of public microarray datasets reveals voltage-gated calcium gene signatures in clinical cancer patients. PLoS One, 10, 2015, e0125766.
42. 42 Kale, V.P., Amin, S.G., Pandey, M.K., Targeting ion channels for cancer therapy by repurposing the approved drugs. Biochim Et Biophys Acta (BBA)-Biomembr 1848 (2015), 2747–2755.
43. 43 Dziegielewska, B., Gray, L.S., Dziegielewski, J., T-type calcium channels blockers as new tools in cancer therapies. Pflugers Arch 466 (2014), 801–810.
44. 44 Ohkubo, T., Yamazaki, J., T-type voltage-activated calcium channel Cav3.1, but not Cav3.2, is involved in the inhibition of proliferation and apoptosis in MCF-7 human breast cancer cells. Int J Oncol 41 (2012), 267–275.
45. 45 Gackiere, F., Bidaux, G., Delcourt, P., van Coppenolle, F., Katsogiannou, M., Dewailly, E., et al. CaV3.2 T-type calcium channels are involved in calcium-dependent secretion of neuroendocrine prostate cancer cells. J Biol Chem 283 (2008), 10162–10173.
46. 46 Latour, I., Louw, D.F., Beedle, A.M., Hamid, J., Sutherland, G.R., Zamponi, G.W., Expression of T-type calcium channel splice variants in human glioma. Glia 48 (2004), 112–119.
47. 47 Wu, L.J., Sweet, T.B., Clapham, D.E., International union of basic and clinical pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Pharmacol Rev 62 (2010), 381–404.
48. 48 Nilius, B., TRP channels in disease. Biochim Biophys Acta 1772 (2007), 805–812.
49. 49 El Hiani, Y., Lehen׳kyi, V., Ouadid-Ahidouch, H., Ahidouch, A., Activation of the calcium-sensing receptor by high calcium induced breast cancer cell proliferation and TRPC1 cation channel over-expression potentially through EGFR pathways. Arch Biochem Biophys 486 (2009), 58–63.
50. 50 Yang, S.L., Cao, Q., Zhou, K.C., Feng, Y.J., Wang, Y.Z., Transient receptor potential channel C3 contributes to the progression of human ovarian cancer. Oncogene 28 (2009), 1320–1328.
51. 51 Aydar, E., Yeo, S., Djamgoz, M., Palmer, C., Abnormal expression, localization and interaction of canonical transient receptor potential ion channels in human breast cancer cell lines and tissues: a potential target for breast cancer diagnosis and therapy. Cancer Cell Int, 9, 2009, 23.
52. 52 Prevarskaya, N., Zhang, L., Barritt, G., TRP channels in cancer. Biochim Biophys Acta 1772 (2007), 937–946.
53. 53 Ouadid-Ahidouch, H., Dhennin-Duthille, I., Gautier, M., Sevestre, H., Ahidouch, A., TRP channels: diagnostic markers and therapeutic targets for breast cancer?. Trends Mol Med 19 (2013), 117–124.
54. 54 Ding, X., He, Z., Shi, Y., Wang, Q., Wang, Y., Targeting TRPC6 channels in oesophageal carcinoma growth. Expert Opin Ther Targets 14 (2010), 513–527.
55. 55 Monet, M., Lehen׳kyi, V., Gackiere, F., Firlej, V., Vandenberghe, M., Roudbaraki, M., et al. Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Cancer Res 70 (2010), 1225–1235.
56. 56 Zhang, L., Barritt, G.J., TRPM8 in prostate cancer cells: a potential diagnostic and prognostic marker with a secretory function?. Endocr-Relat Cancer 13 (2006), 27–38.
57. 57 Zhang, S.S., Wen, J., Yang, F., Cai, X.L., Yang, H., Luo, K.J., et al. High expression of transient potential receptor C6 correlated with poor prognosis in patients with esophageal squamous cell carcinoma. Med Oncol, 30, 2013, 607.
58. 58 Tsavaler, L., Shapero, M.H., Morkowski, S., Laus, R., Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 61 (2001), 3760–3769.
59. 59 Dhennin-Duthille, I., Gautier, M., Faouzi, M., Guilbert, A., Brevet, M., Vaudry, D., et al. High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters. Cell Physiol Biochem 28 (2011), 813–822.
60. 60 Guilbert, A., Gautier, M., Dhennin-Duthille, I., Haren, N., Sevestre, H., Ouadid-Ahidouch, H., Evidence that TRPM7 is required for breast cancer cell proliferation. Am J Physiol Cell Physiol 297 (2009), C493–C502.
61. 61 Chodon, D., Guilbert, A., Dhennin-Duthille, I., Gautier, M., Telliez, M.S., Sevestre, H., et al. Estrogen regulation of TRPM8 expression in breast cancer cells. BMC Cancer, 10, 2010, 212.
62. 62 Clark, K., Middelbeek, J., van Leeuwen, F.N., Interplay between TRP channels and the cytoskeleton in health and disease. Eur J Cell Biol 87 (2008), 631–640.
63. 2+ entry through STIM and ORAI proteins in immunity, hemostasis and cancer. Channels (Austin) 2013;7:379-91.
64. 64 Yang, S., Zhang, J.J., Huang, X.Y., Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell 15 (2009), 124–134.
65. 65 Motiani, R.K., Hyzinski-Garcia, M.C., Zhang, X., Henkel, M.M., Abdullaev, I.F., Kuo, Y.H., et al. STIM1 and Orai1 mediate CRAC channel activity and are essential for human glioblastoma invasion. Pflugers Arch 465 (2013), 1249–1260.
66. 66 Kondratska, K., Kondratskyi, A., Yassine, M., Lemonnier, L., Lepage, G., Morabito, A., et al. Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma. Biochim Biophys Acta 1843 (2014), 2263–2269.
67. 67 Flourakis, M., Lehen׳kyi, V., Beck, B., Raphael, M., Vandenberghe, M., Abeele, F.V., et al. Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. Cell Death Dis, 1, 2010, e75.
68. 68 Dubois, C., Vanden Abeele, F., Lehen׳kyi, V., Gkika, D., Guarmit, B., Lepage, G., et al. Remodeling of channel-forming ORAI proteins determines an oncogenic switch in prostate cancer. Cancer Cell 26 (2014), 19–32.
69. 2+ entry inhibits hepatocarcinoma cell migration and invasion by regulating focal adhesion turnover. Cancer Lett 330 (2013), 163–169.
70. 70 Kim, J.H., Lkhagvadorj, S., Lee, M.R., Hwang, K.H., Chung, H.C., Jung, J.H., et al. Orai1 and STIM1 are critical for cell migration and proliferation of clear cell renal cell carcinoma. Biochem Biophys Res Commun 448 (2014), 76–82.
71. + T cells. EMBO Mol Med 5 (2013), 1311–1321.
72. 72 Oh-Hora, M., Yamashita, M., Hogan, P.G., Sharma, S., Lamperti, E., Chung, W., et al. Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance. Nat Immunol 9 (2008), 432–443.
73. 73 Aytes, A., Mollevi, D.G., Martinez-Iniesta, M., Nadal, M., Vidal, A., Morales, A., et al. Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype. Mol Carcinog 51 (2012), 746–753.
74. 74 Stanisz, H., Saul, S., Muller, C.S., Kappl, R., Niemeyer, B.A., Vogt, T., et al. Inverse regulation of melanoma growth and migration by Orai1/STIM2-dependent calcium entry. Pigment Cell Melanoma Res 27 (2014), 442–453.
75. 75 Faouzi, M., Hague, F., Potier, M., Ahidouch, A., Sevestre, H., Ouadid-Ahidouch, H., Down-regulation of Orai3 arrests cell-cycle progression and induces apoptosis in breast cancer cells but not in normal breast epithelial cells. J Cell Physiol 226 (2011), 542–551.
76. 76 Ay, A.S., Benzerdjerb, N., Sevestre, H., Ahidouch, A., Ouadid-Ahidouch, H., Orai3 constitutes a native store-operated calcium entry that regulates non small cell lung adenocarcinoma cell proliferation. PLoS One, 8, 2013, e72889.
77. 2+ channel that promotes tumorigenesis. Faseb J 27 (2013), 63–75.
78. 78 Motiani, R.K., Abdullaev, I.F., Trebak, M., A novel native store-operated calcium channel encoded by Orai3: selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen receptor-negative breast cancer cells. J Biol Chem 285 (2010), 19173–19183.
79. 79 Pan, Z., Ma, J., Open Sesame: treasure in store-operated calcium entry pathway for cancer therapy. Sci China Life Sci 58 (2015), 48–53.
80. 80 Giannuzzo, A., Pedersen, S.F., Novak, I., The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells. Mol Cancer 14 (2015), 1–15.
81. 81 Jin, H., Eun, S.Y., Lee, J.S., Park, S.W., Lee, J.H., Chang, K.C., et al. P2Y2 receptor activation by nucleotides released from highly metastatic breast cancer cells increases tumor growth and invasion via crosstalk with endothelial cells. Breast Cancer Res, 16, 2014, R77.
82. 82 Xie, R., Xu, J., Wen, G., Jin, H., Liu, X., Yang, Y., et al. The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP. J Biol Chem 289 (2014), 19137–19149.
83. 83 Nylund, G., Hultman, L., Nordgren, S., Delbro, D.S., P2Y2- and P2Y4 purinergic receptors are over-expressed in human colon cancer. Auton Autacoid Pharmacol 27 (2007), 79–84.
84. 84 Maynard, J.P., Lee, J.S., Sohn, B.H., Yu, X., Lopez-Terrada, D., Finegold, M.J., et al. P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients. Oncotarget 6 (2015), 41162–41179.
85. 2+ uniporter. Cell Metab 17 (2013), 976–987.
86. 86 Brookes, P.S., Yoon, Y., Robotham, J.L., Anders, M.W., Sheu, S.S., Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 287 (2004), C817–C833.
87. 87 Curry, M.C., Peters, A.A., Kenny, P.A., Roberts-Thomson, S.J., Monteith, G.R., Mitochondrial calcium uniporter silencing potentiates caspase-independent cell death in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 434 (2013), 695–700.
88. 88 Marchi, S., Lupini, L., Patergnani, S., Rimessi, A., Missiroli, S., Bonora, M., et al. Downregulation of the mitochondrial calcium uniporter by cancer-related miR-25. Curr Biol 23 (2013), 58–63.
89. 2+ uptake that regulates cell survival. Cell 151 (2012), 630–644.
90. 90 Ding, X., He, Z., Zhou, K., Cheng, J., Yao, H., Lu, D., et al. Essential role of TRPC6 channels in G2/M phase transition and development of human glioma. J Natl Cancer Inst 102 (2010), 1052–1068.
91. 91 Duncan, L.M., Deeds, J., Hunter, J., Shao, J., Holmgren, L.M., Woolf, E.A., et al. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 58 (1998), 1515–1520.
92. 92 Yee, N.S., Chan, A.S., Yee, J.D., Yee, R.K., TRPM7 and TRPM8 ion channels in pancreatic adenocarcinoma: potential roles as cancer biomarkers and targets. Sci (Cairo), 2012, 415158.
93. 93 Liu, Y., Qin, N., TRPM8 in health and disease: cold sensing and beyond. Adv Exp Med Biol 704 (2011), 185–208.
94. 94 Kalogris, C., Caprodossi, S., Amantini, C., Lambertucci, F., Nabissi, M., Morelli, M.B., et al. Expression of transient receptor potential vanilloid-1 (TRPV1) in urothelial cancers of human bladder: relation to clinicopathological and molecular parameters. Histopathology 57 (2010), 744–752.
95. 95 Sanchez, M.G., Sanchez, A.M., Collado, B., Malagarie-Cazenave, S., Olea, N., Carmena, M.J., et al. Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue. Eur J Pharmacol 515 (2005), 20–27.
96. 96 Perálvarez-Marín, A., Doñate-Macian, P., Gaudet, R., What do we know about the transient receptor potential vanilloid 2 (TRPV2) ion channel?. FEBS J 280 (2013), 5471–5487.
97. 97 Fusi, C., Materazzi, S., Minocci, D., Maio, V., Oranges, T., Massi, D., et al. Transient receptor potential vanilloid 4 (TRPV4) is downregulated in keratinocytes in human non-melanoma skin cancer. J Invest Dermatol 134 (2014), 2408–2417.
98. 98 Adapala, R.K., Thoppil, R.J., Ghosh, K., Cappelli, H.C., Dudley, A.C., Paruchuri, S., et al. Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy. Oncogene 35 (2016), 314–322.
99. 99 Fiorio Pla, A., Ong, H.L., Cheng, K.T., Brossa, A., Bussolati, B., Lockwich, T., et al. TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated actin remodeling. Oncogene 31 (2012), 200–212.
100. 100 Raphael, M., Lehen׳kyi, V., Vandenberghe, M., Beck, B., Khalimonchyk, S., Vanden Abeele, F., et al. TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival. Proc Natl Acad Sci U S A, 2014.
101. 101 Lau, J.K., Brown, K.C., Dom, A.M., Witte, T.R., Thornhill, B.A., Crabtree, C.M., et al. Capsaicin induces apoptosis in human small cell lung cancer via the TRPV6 receptor and the calpain pathway. Apoptosis 19 (2014), 1190–1201.
102. 102 Peters, A.A., Simpson, P.T., Bassett, J.J., Lee, J.M., Da Silva, L., Reid, L.E., et al. Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer. Mol Cancer Ther 11 (2012), 2158–2168.
103. 103 Vy, Lehen'kyi, Raphaël, M., Prevarskaya, N., The role of the TRPV6 channel in cancer. J Physiol 590 (2012), 1369–1376.
104. 2+ oscillation orchestrates invadopodium formation and melanoma invasion. J Cell Biol 207 (2014), 535–548.
105. 105 Moccia, F., Dragoni, S., Poletto, V., Rosti, V., Tanzi, F., Ganini, C., et al. Orai1 and transient receptor potential channels as novel molecular targets to impair tumor neovascularization in renal cell carcinoma and other malignancies. Anti-Cancer Agents Med Chem 14 (2014), 296–312.
106. 106 Zhan, Z.Y., Zhong, L.X., Feng, M., Wang, J.F., Liu, D.B., Xiong, J.P., Over-expression of Orai1 mediates cell proliferation and associates with poor prognosis in human non-small cell lung carcinoma. Int J Clin Exp Pathol 8 (2015), 5080–5088.
107. 107 Chen, Y.F., Chiu, W.T., Chen, Y.T., Lin, P.Y., Huang, H.J., Chou, C.Y., et al. Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis. Proc Natl Acad Sci U S A 108 (2011), 15225–15230.
108. 108 Wang, J.Y., Sun, J., Huang, M.Y., Wang, Y.S., Hou, M.F., Sun, Y., et al. STIM1 overexpression promotes colorectal cancer progression, cell motility and COX-2 expression. Oncogene 34 (2015), 4358–4367.
109. 109 McAndrew, D., Grice, D.M., Peters, A.A., Davis, F.M., Stewart, T., Rice, M., et al. ORAI1-mediated calcium influx in lactation and in breast cancer. Mol Cancer Ther 10 (2011), 448–460.
110. 2+ remodeling and cancer hallmarks in colorectal carcinoma cells. J Biol Chem 289 (2014), 28765–28782.
111. 111 Yao, S., Gallenkamp, D., Wolfel, K., Luke, B., Schindler, M., Scherkenbeck, J., Synthesis and SERCA activities of structurally simplified cyclopiazonic acid analogues. Bioorg Med Chem 19 (2011), 4669–4678.
112. 112 Denmeade, S.R., Mhaka, A.M., Rosen, D.M., Brennen, W.N., Dalrymple, S., Dach, I., et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med, 4, 2012, 140ra86.
113. 113 Wong, V.K., Li, T., Law, B.Y., Ma, E.D., Yip, N.C., Michelangeli, F., et al. Saikosaponin-d, a novel SERCA inhibitor, induces autophagic cell death in apoptosis-defective cells. Cell Death Dis, 4, 2013, e720.
114. 2+ ATPase pump, induces autophagy, endoplasmic reticulum stress, and apoptosis. Mol Cancer Ther 9 (2010), 718–730.
115. 115 Bergamo, A., Masi, A., Jakupec, M.A., Keppler, B.K., Sava, G., Inhibitory effects of the ruthenium complex KP1019 in models of mammary cancer cell migration and invasion. Metal-Based Drugs, 2009, 681270.
116. 116 Yang, B., Zhang, M., Gao, J., Li, J., Fan, L., Xiang, G., et al. Small molecule RL71 targets SERCA2 at a novel site in the treatment of human colorectal cancer. Oncotarget 6 (2015), 37613–37625.
117. 117 Muscella, A., Calabriso, N., Vetrugno, C., Fanizzi, F.P., De Pascali, S.A., Storelli, C., et al. The platinum (II) complex [Pt(O,O׳-acac)(γ-acac)(DMS)] alters the intracellular calcium homeostasis in MCF-7 breast cancer cells. Biochem Pharmacol 81 (2011), 91–103.
118. 2+ levels in human lung adenocarcinoma A549 cells. Bioorg Med Chem Lett 22 (2012), 7123–7126.
119. 2+ channel inhibitor, inhibits angiogenesis via suppression of hypoxia-inducible factor-1α signal transduction. J Mol Med (Berl) 93 (2015), 499–509.
120. 2+ channel blocker, in human epidermoid carcinoma A431 cells. Biochem Pharmacol 73 (2007), 943–953.
121. 121 Garrido-Laguna, I., Tan, A.C., Villarroel, M.C., Rajeshkumar, N., Rubio-Viqueira, B., Gray, L., et al. Activity of the T-type calcium channel antagonist Mibefradil in pancreatic cancer xenografts. Clin Cancer Res, 14, 2008 [B49-B49].
122. 2+ channel expression in PC-3 human prostate carcinoma cells. Biochem Biophys Res Commun 403 (2010), 24–29.
123. 123 Shigetomi, E., Tong, X., Kwan, K.Y., Corey, D.P., Khakh, B.S., TRPA1 channels regulate astrocyte resting calcium and inhibitory synapse efficacy through GAT-3. Nat Neurosci 15 (2012), 70–80.
124. 124 Dasari, R., De Carvalho, A., Medellin, D.C., Middleton, K.N., Hague, F., Volmar, M.N., et al. Wittig derivatization of sesquiterpenoid polygodial leads to cytostatic agents with activity against drug resistant cancer cells and capable of pyrrolylation of primary amines. Eur J Med Chem 103 (2015), 226–237.
125. 125 Hwang, J.A., Hwang, M.K., Jang, Y., Lee, E.J., Kim, J.E., Oh, M.H., et al. 20-O-β-d-glucopyranosyl-20(S)-protopanaxadiol, a metabolite of ginseng, inhibits colon cancer growth by targeting TRPC channel-mediated calcium influx. J Nutr Biochem 24 (2013), 1096–1104.
126. 126 Zhu, Y., Lu, Y., Qu, C., Miller, M., Tian, J., Thakur, D.P., et al. Identification and optimization of 2-aminobenzimidazole derivatives as novel inhibitors of TRPC4 and TRPC5 channels. Br J Pharmacol 172 (2015), 3495–3509.
127. 127 He, L.P., Hewavitharana, T., Soboloff, J., Spassova, M.A., Gill, D.L., A functional link between store-operated and TRPC channels revealed by the 3,5-bis(trifluoromethyl)pyrazole derivative, BTP2. J Biol Chem 280 (2005), 10997–11006.
128. 128 Vigont, V.A., Zimina, O.A., Glushankova, L.N., Bezprozvanny, I.B., Mozhayeva, G.N., Kaznacheyeva, E.V., Store-operated calcium entry into SK-N-SH human neuroblastoma cells modeling huntington׳s disease. Biochem (Mosc) Suppl Ser A: Membr Cell Biol 6 (2012), 206–214.
129. 129 Akbulut, Y., Gaunt, H.J., Muraki, K., Ludlow, M.J., Amer, M.S., Bruns, A., et al. (−)-Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels. Angew Chem Int Ed Engl 54 (2015), 3787–3791.
130. 130 Carson, C., Raman, P., Tullai, J., Xu, L., Henault, M., Thomas, E., et al. Englerin A agonizes the TRPC4/C5 cation channels to inhibit tumor cell line proliferation. PLoS One, 10, 2015, e0127498.
131. 131 Miller, M., Shi, J., Zhu, Y., Kustov, M., Tian, J.B., Stevens, A., et al. Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. J Biol Chem 286 (2011), 33436–33446.
132. 132 Seo, K., Rainer, P.P., Hahn, V.S., Lee, D.I., Jo, S.H., Andersen, A., et al. Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy. Proc Natl Acad Sci U S A 111 (2014), 1551–1556.
133. 133 Madan, E., Gogna, R., Keppler, B., Pati, U., p53 increases intra-cellular calcium release by transcriptional regulation of calcium channel TRPC6 in GaQ3-treated cancer cells. PLoS One, 8, 2013, e71016.
134. 134 Gonzales, C.B., Kirma, N.B., De La Chapa, J.J., Chen, R., Henry, M.A., Luo, S., et al. Vanilloids induce oral cancer apoptosis independent of TRPV1. Oral Oncol 50 (2014), 437–447.
135. 135 Yang, F., Xiao, X., Cheng, W., Yang, W., Yu, P., Song, Z., et al. Structural mechanism underlying capsaicin binding and activation of the TRPV1 ion channel. Nat Chem Biol 11 (2015), 518–524.
136. 136 Costa, B., Giagnoni, G., Franke, C., Trovato, A.E., Colleoni, M., Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 143 (2004), 247–250.
137. 137 Liu, T., Wang, G., Tao, H., Yang, Z., Wang, Y., Meng, Z., et al. Capsaicin mediates caspases activation and induces apoptosis through P38 and JNK MAPK pathways in human renal carcinoma. BMC Cancer, 16, 2016, 790.
138. 138 de Jong, P.R., Takahashi, N., Harris, A.R., Lee, J., Bertin, S., Jeffries, J., et al. Ion channel TRPV1-dependent activation of PTP1B suppresses EGFR-associated intestinal tumorigenesis. J Clin Invest 124 (2014), 3793–3806.
139. 139 Juvin, V., Penna, A., Chemin, J., Lin, Y.L., Rassendren, F.A., Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxydiphenyl borate. Mol Pharmacol 72 (2007), 1258–1268.
140. 140 Velasco, G., Hernández-Tiedra, S., Dávila, D., Lorente, M., The use of cannabinoids as anticancer agents. Prog Neuro-Psychopharmacol Biol Psychiatry 64 (2016), 259–266.
141. 2+-permeable channel. Cell Calcium 22 (1997), 75–82.
142. 142 Thorneloe, K.S., Sulpizio, A.C., Lin, Z., Figueroa, D.J., Clouse, A.K., McCafferty, G.P., et al. N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: part I. J Pharmacol Exp Ther 326 (2008), 432–442.
143. 143 Thorneloe, K.S., Bao, W., Alsaid, H., Jian, M.-Y., Costell, M., Maniscalco, K., et al. Discovery of orally active transient receptor potential vanilloid 4 (TRPV4) blockers for the treatment of pulmonary edema in heart failure. Circulation, 124, 2011, A13510.
144. 144 Wei, Z.L., Nguyen, M.T., O׳Mahony, D.J., Acevedo, A., Zipfel, S., Zhang, Q., et al. Identification of orally-bioavailable antagonists of the TRPV4 ion-channel. Bioorg Med Chem Lett 25 (2015), 4011–4015.
145. 2+ influx and cytokine production by facilitating transient receptor potential melastatin 4 channel activity. Mol Pharmacol 69 (2006), 1413–1420.
146. 146 De Petrocellis, L., Ligresti, A., Moriello, A.S., Allara, M., Bisogno, T., Petrosino, S., et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163 (2011), 1479–1494.
147. 147 Almeida, M.C., Hew-Butler, T., Soriano, R.N., Rao, S., Wang, W., Wang, J., et al. Pharmacological blockade of the cold receptor TRPM8 attenuates autonomic and behavioral cold defenses and decreases deep body temperature. J Neurosci 32 (2012), 2086–2099.
148. 148 Yee NS. Roles of TRPM8 ion channels in cancer: proliferation, survival, and invasion Cancers (Basel) 2015;7:2134-2146.
149. 149 Tolcher, A., Patnaik, A., Papadopoulos, K., Mays, T., Stephan, T., Humble, D.J., et al. 376 Preliminary results from a Phase 1 study of D-3263 HCl, a TRPM8 calcium channel agonist, in patients with advanced cancer. Eur J Cancer Suppl, 8, 2010, 119.
150. 150 Wang, W., Gao, Q., Yang, M., Zhang, X., Yu, L., Lawas, M., et al. Up-regulation of lysosomal TRPML1 channels is essential for lysosomal adaptation to nutrient starvation. Proc Natl Acad Sci U S A 112 (2015), E1373–E1381.
151. 151 Chen, C.C., Keller, M., Hess, M., Schiffmann, R., Urban, N., Wolfgardt, A., et al. A small molecule restores function to TRPML1 mutant isoforms responsible for mucolipidosis type IV. Nat Commun, 5, 2014, 4681.
152. 152 Landowski, C.P., Bolanz, K.A., Suzuki, Y., Hediger, M.A., Chemical inhibitors of the calcium entry channel TRPV6. Pharm Res 28 (2011), 322–330.
153. 153 Bowen, C.V., DeBay, D., Ewart, H.S., Gallant, P., Gormley, S., Ilenchuk, T.T., et al. In vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin. PLoS One, 8, 2013, e58866.
154. 2+ entry. Cancer Res 60 (2000), 1002–1008.
155. 155 Perabo, F.G., Wirger, A., Kamp, S., Lindner, H., Schmidt, D.H., Muller, S.C., et al. Carboxyamido-triazole (CAI), a signal transduction inhibitor induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2. Anticancer Res 24 (2004), 2869–2877.
156. 156 Harper, J.L., Camerini-Otero, C.S., Li, A.-H., Kim, S.-A., Jacobson, K.A., Daly, J.W., Dihydropyridines as inhibitors of capacitative calcium entry in leukemic HL-60 cells. Biochem Pharmacol 65 (2003), 329–338.
157. 157 Yoshino, T., Ishikawa, J., Ohga, K., Morokata, T., Takezawa, R., Morio, H., et al. YM-58483, a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models. Eur J Pharmacol 560 (2007), 225–233.
158. 158 Dutcher, J.P., Leon, L., Manola, J., Friedland, D.M., Roth, B., Wilding, G., Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: e4896, an Eastern Cooperative Oncology Group Study. Cancer 104 (2005), 2392–2399.
159. 159 Moody, T.W., Chiles, J., Moody, E., Sieczkiewicz, G.J., Kohn, E.C., CAI inhibits the growth of small cell lung cancer cells. Lung Cancer 39 (2003), 279–288.
160. 2+-store-dependent and -independent reversal of Stim1 localization and function. J Cell Sci 121 (2008), 762–772.
161. 161 Kondratskyi, A., Yassine, M., Slomianny, C., Kondratska, K., Gordienko, D., Dewailly, E., et al. Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death. Cell Death Dis, 5, 2014, e1193.
162. 162 McNally, B.A., Somasundaram, A., Yamashita, M., Prakriya, M., Gated regulation of CRAC channel ion selectivity by STIM1. Nature 482 (2012), 241–245.
163. 163 Yeromin, A.V., Zhang, S.L., Jiang, W., Yu, Y., Safrina, O., Cahalan, M.D., Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai. Nature 443 (2006), 226–229.
164. 164 Sampath, B., Sankaranarayanan, K., Glu106 targeted inhibitors of ORAI1 as potential Ca release-activated Ca (CRAC) channel blockers - molecular modeling and docking studies. J Recept Signal Transduct Res, 2016, 1–14.
165. 165 Derler, I., Schindl, R., Fritsch, R., Heftberger, P., Riedl, M.C., Begg, M., et al. The action of selective CRAC channel blockers is affected by the Orai pore geometry. Cell Calcium 53 (2013), 139–151.
166. 166 Sadaghiani, A.M., Lee, S.M., Odegaard, J.I., Leveson-Gower, D.B., McPherson, O.M., Novick, P., et al. Identification of Orai1 channel inhibitors by using minimal functional domains to screen small molecule microarrays. Chem Biol 21 (2014), 1278–1292.
167. 3 receptors. J Physiol 536 (2001), 3–19.
168. 2+ entry via STIM proteins. Cell Calcium 47 (2010), 1–10.
169. 169 Chen, G., Panicker, S., Lau, K.Y., Apparsundaram, S., Patel, V.A., Chen, S.L., et al. Characterization of a novel CRAC inhibitor that potently blocks human T cell activation and effector functions. Mol Immunol 54 (2013), 355–367.
170. 170 Small, E.J., Meyer, M., Marshall, M.E., Reyno, L.M., Meyers, F.J., Natale, R.B., et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18 (2000), 1440–1450.
171. 171 Adinolfi, E., Raffaghello, L., Giuliani, A.L., Cavazzini, L., Capece, M., Chiozzi, P., et al. Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res 72 (2012), 2957–2969.
172. 172 Adinolfi, E., Capece, M., Amoroso, F., De Marchi, E., Franceschini, A., Emerging roles of P2X receptors in cancer. Curr Med Chem 22 (2015), 878–890.
173. 173 Mariot, P., Prevarskaya, N., Roudbaraki, M.M., Le Bourhis, X., Van Coppenolle, F., Vanoverberghe, K., et al. Evidence of functional ryanodine receptor involved in apoptosis of prostate cancer (LNCaP) cells. Prostate 43 (2000), 205–214.
174. 174 Abdul, M., Ramlal, S., Hoosein, N., Ryanodine receptor expression correlates with tumor grade in breast cancer. Pathol Oncol Res 14 (2008), 157–160.
175. 175 Garcia-Prieto, C., Riaz Ahmed, K.B., Chen, Z., Zhou, Y., Hammoudi, N., Kang, Y., et al. Effective killing of leukemia cells by the natural product OSW-1 through disruption of cellular calcium homeostasis. J Biol Chem 288 (2013), 3240–3250.
176. 2+-exchanger in HCT116 human colonolocancer cells. Arch Pharm Res 31 (2008), 54–59.
177. 177 Lee, Y.S., Wurster, R.D., Bepridil enhances in vitro antitumor activity of antiestrogens in human brain tumor cells. Cancer Lett 110 (1996), 243–248.
178. 2+ exchange of heart mitochondria by benzothiazepine CGP-37157. J Cardiovasc Pharmacol 21 (1993), 595–599.
179. 2+ exchanger, decreases early and delayed afterdepolarizations in the canine heart. Br J Pharmacol 170 (2013), 768–778.
180. 2+ exchanger, blocks N-methyl-D-aspartate receptor and inhibits mitochondrial complex I. Br J Pharmacol 162 (2011), 255–270.
181. 2+. Br J Pharmacol 171 (2014), 3432–3447.
182. 2+ signalling in cultured rat myotubes, isolated myonuclei, and neuroblastoma (NG108-15) cells. FEBS Lett 579 (2005), 2051–2057.
183. 3 receptor, attenuates the positive inotropic effect of α-adrenergic stimulation in guinea-pig papillary muscle. Br J Pharmacol 130 (2000), 650–654.
184. 2+ transfer from endoplasmic reticulum to mitochondria. Cell Rep 14 (2016), 2313–2324.
185. 2+ release. J Biochem 122 (1997), 498–505.
186. 3) receptor. Br J Pharmacol 171 (2014), 3298–3312.
187. 3R subtype 3 by caffeine slows glioblastoma invasion and migration and extends survival. Cancer Res 70 (2010), 1173–1183.
188. 2+ by caffeine and ryanodine induces apoptosis of chinese hamster ovary cells transfected with ryanodine receptor. J Biol Chem 275 (2000), 19978–19984.
189. 189 Piedras-Rentería, E.S., Barrett, C.F., Cao, Y.-Q., Tsien, R.W., Voltage-gated calcium channels, calcium signaling, and channelopathies. Joachim, K., Marek, M., (eds.) New Comprehensive Biochemistry, 2007, Amsterdam: Elsevier, 127–166.
190. rd, Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine. Cancer Res 50 (1990), 5399–5405.
191. 191 Krouse, A.J., Gray, L., Macdonald, T., McCray, J., Repurposing and rescuing of mibefradil, an antihypertensive, for cancer: a case study. Assay Drug Dev Technol 13 (2015), 650–653.
192. 192 Bruce, J.I.E., Elliott, A.C., Pharmacological evaluation of the role of cytochrome P450 in intracellular calcium signalling in rat pancreatic acinar cells. Br J Pharmacol 131 (2000), 761–771.
193. 193 Merritt, J.E., Armstrong, W.P., Benham, C.D., Hallam, T.J., Jacob, R., Jaxa-Chamiec, A., et al. SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. Biochem J 271 (1990), 515–522.
194. 194 Zeng, B., Yuan, C., Yang, X., Atkin, S.L., Xu, S.Z., TRPC channels and their splice variants are essential for promoting human ovarian cancer cell proliferation and tumorigenesis. Curr Cancer Drug Targets 13 (2013), 103–116.
195. 195 Sanchez, A.M., Sanchez, M.G., Malagarie-Cazenave, S., Olea, N., Diaz-Laviada, I., Induction of apoptosis in prostate tumor PC-3 cells and inhibition of xenograft prostate tumor growth by the vanilloid capsaicin. Apoptosis 11 (2006), 89–99.
196. 196 Ramer, R., Bublitz, K., Freimuth, N., Merkord, J., Rohde, H., Haustein, M., et al. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. Faseb J 26 (2012), 1535–1548.
197. 197 Trebak, M., Bird, G.S., McKay, R.R., Putney, J.W. Jr., Comparison of human TRPC3 channels in receptor-activated and store-operated modes. Differential sensitivity to channel blockers suggests fundamental differences in channel composition. J Biol Chem 277 (2002), 21617–21623.
198. 2+ channel gating by STIM1 and 2-aminoethyldiphenyl borate. J Biol Chem 286 (2011), 9429–9442.
199. 199 Schindl, R., Bergsmann, J., Frischauf, I., Derler, I., Fahrner, M., Muik, M., et al. 2-aminoethoxydiphenyl borate alters selectivity of Orai3 channels by increasing their pore size. J Biol Chem 283 (2008), 20261–20267.
200. 2+ channel. J General Physiol 143 (2014), 325–343.
201. 201 Ma, H.T., Venkatachalam, K., Parys, J.B., Gill, D.L., Modification of store-operated channel coupling and inositol trisphosphate receptor function by 2-aminoethoxydiphenyl borate in DT40 lymphocytes. J Biol Chem 277 (2002), 6915–6922.
202. 2+ (CRAC) current. Biochem J 441 (2012), 743–753.
203. 2+-dependent fast inactivation of CRAC channels: evidence for coupling of permeation and gating. J Gen Physiol 130 (2007), 525–540.
204. 204 Jairaman, A., Prakriya, M., Molecular pharmacology of store-operated CRAC channels. Channels (Austin) 7 (2013), 402–414.
205. 2+ entry pathways. Br J Pharmacol 167 (2012), 1712–1722.
206. 2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2. J Biol Chem 279 (2004), 12427–12437.
207. 2+ channels. J Biol Chem 283 (2008), 31348–31355.
208. 2+ entry and migration of vascular smooth muscle cells. Br J Pharmacol 164 (2011), 382–393.
209. 209 Ramos, S., Grigoryev, S., Rogers, E., Roos, J., Whitten, J., Stauderman, K., et al. CM3457, a potent and selective oral CRAC channel inhibitor, suppresses T and mast cell function and is efficacious in rat models of arthritis and asthma. J Immunol, 188, 2012, 72.3.
210. 210 Lin, F.F., Elliott, R., Colombero, A., Gaida, K., Kelley, L., Moksa, A., et al. Generation and characterization of fully human monoclonal antibodies against human Orai1 for autoimmune disease. J Pharmacol Exp Ther 345 (2013), 225–238.
211. 211 Cox, J.H., Hussell, S., Sondergaard, H., Roepstorff, K., Bui, J.V., Deer, J.R., et al. Antibody-mediated targeting of the Orai1 calcium channel inhibits T cell function. PLoS One, 8, 2013, e82944.